{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sela M"],"funding":["Israel National Institute for Health Policy Research","European Research Council","Israel Science Foundation","Phospholipid Research Center","Teva Pharmaceutical Industries","Michael J. Fox Foundation for Parkinson's Research"],"pagination":["e2304654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615408"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(51)"],"pubmed_abstract":["Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although poor delivery to the brain hinders their therapeutic application. In the current study, it is demonstrated that brain-targeted liposomes (BTL) enhance the delivery of mAbs across the blood-brain-barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of the PD brain. BTL are decorated with transferrin to improve brain targeting through overexpressed transferrin-receptors on the BBB during PD. BTL are loaded with SynO4, a mAb that inhibits alpha-synuclein (AS) aggregation, a pathological hallmark of PD. It is shown that 100-nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to"],"journal":["Advanced materials (Deerfield Beach, Fla.)"],"pubmed_title":["Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease."],"pmcid":["PMC7615408"],"funding_grant_id":["101089009","1881/21","101040128","2248/19","851765","1384/21","MJFF‐022407","1R21AG074846‐01A1","2141/20","1934/23","ASC‐2018‐062/1‐1","2359/23"],"pubmed_authors":["Choudhary A","Weiss Y","Kagan S","Schroeder JE","Avital A","Adir O","Odeh A","Berdichevsky Y","Yeretz-Peretz Y","Aga-Mizrachi S","Ben-Zvi A","Kaduri M","Hershkovitz D","Ashery U","Hasson P","Schroeder A","Rozencweig A","Mora-Raimundo P","Bell B","Rosh I","Shklover J","Shainsky-Roitman J","Ashkenazi A","Chen G","Simchi L","Laviv T","Stern S","Sela M","Poley M","Leichtmann-Bardoogo Y","Cordeiro D","Sade O","Maoz BM","Or AZ","Cohen-Adiv S"],"additional_accession":[]},"is_claimable":false,"name":"Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease.","description":"Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although poor delivery to the brain hinders their therapeutic application. In the current study, it is demonstrated that brain-targeted liposomes (BTL) enhance the delivery of mAbs across the blood-brain-barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of the PD brain. BTL are decorated with transferrin to improve brain targeting through overexpressed transferrin-receptors on the BBB during PD. BTL are loaded with SynO4, a mAb that inhibits alpha-synuclein (AS) aggregation, a pathological hallmark of PD. It is shown that 100-nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-18T16:07:59.69Z","creation":"2025-04-07T03:07:40.357Z"},"accession":"S-EPMC7615408","cross_references":{"pubmed":["37753928"],"doi":["10.1002/adma.202304654"]}}